BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the
Company plans to release its first quarter 2016 financial results
and reaffirm guidance on Thursday, May 5,
2016, before the opening of the U.S. financial markets. The
earnings press release will be accessible through the Investor
Relations section of the Company's website,
www.anipharmaceuticals.com.
Arthur S. Przybyl, President and
Chief Executive Officer, and Charlotte C.
Arnold, Vice President, Finance, and Chief Financial
Officer, also plan to host a conference call to review those
results starting at 10:30am Eastern
Time on Thursday, May 5, 2016.
The call will be open to the public and can be accessed through a
conference line by dialing (844) 295-8236.
Mr. Przybyl stated, "We look forward to speaking with the
investor community, releasing our first quarter results, and
reaffirming our 2016 guidance as updated in early April."
A recording of the conference call will be available within two
hours of the completion of the call and will remain accessible for
a period of seven days following the call. To access the replay,
dial (855) 859-2056. The access code for the replay is
93601942.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include controlled substances, oncolytics
(anti-cancers), hormones and steroids, and complex formulations
involving extended release and combination products. For more
information, please visit our website
www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2016-financial-results-and-reaffirm-guidance-300258123.html
SOURCE ANI Pharmaceuticals, Inc.